000 06310nam a22004575i 4500
999 _c120530
_d120530
_x1
001 120530
003 ES-MaUEC
005 20230102114047.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 200409s2020 gw a o |||| 0|eng d
020 _a9783030345211
024 7 _a10.1007/978-3-030-34521-1
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aQP609.P78
_b2020 EB
245 0 0 _aHeparanase :
_bFrom Basic Research to Clinical Applications
_cedited by Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan
250 _aFirst edition
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2020
300 _a1 recurso en línea (XVIII, 885 páginas)
_b168 ilustraciones, 107 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aAdvances in Experimental Medicine and Biology
_x0065-2598
_v1221
490 0 _aBiomedical and Life Sciences (Springer-11642)
505 0 _aSection 1: Historical Background -- Chapter 1: Mast cell/platelet heparanase/Heparan sulfate biosynthesis and turnover -- Chapter 2: gene cloning/overview -- Chapter 3: gene cloning/melanoma metastasis -- Chapter 4: gene cloning/cancer/immune system -- Chapter 5: heparin/HS modifying enzymes -- Section 2: Crystal Structure/substrate specificity/gene regulation -- Chapter 6: crystal structure -- Chapter 7: molecular dynamics, KKDC peptide -- Chapter 8: Biochemistry/active site -- Chapter 9: substrate specificity -- Chapter 10: gene regulation, promoter/Egr1/methylation -- Chapter 11: SNPs -- polymorphism -- Chapter 12: Splice variants -- Section 3: Cell & tumor biology (general functions & mode of action) -- Chapter 13: Exosomes/heparan sulfate/heparanse -- Chapter 14: Exosomes/drug resistance -- Chapter 15: Nuclear heparanse/transcriptional activity -- Chapter 16: Non-Enzymatic functions/Signal transduction/cellular trafficking/autophagy -- Chapter 17: Heparan sulfate/stem cells/inflammation -- Chapter 18: Danger signals/HS/platelet heparanse -- Chapter 19: Heparanse/Intergrins/Melanoma -- Section 3: Immune Cells/Immnuno-Modulation -- Chapter 20: Heparain. Heparanse and Selectins in Cancer Metastasis and Inflamation --- Chapter 21: Trans-Endithelial Migration, Lymphocytes, Neutrophils/T-cells --Chapter 22: Macrophages, dendritic cells, autoimmunity -- Chapter 23: Macrophages, Heparanse and the tumor microenvironment, neutralizing antibodies -- Chapter 24: NK Cells -- Section 4: Cancer (heparanse in specific types of cancer) -- Chapter 25: Myeloma, inhbition, drug resistance -- Chapter 26: Breast Cancer/Pancreatic Cancer/Cancer and Inflammation -- Chapter 27: Brain Metastasis/MIR-1258 -- Chapter 28: Gastric cancer/immunization -- Chapter 29: Head and Neck Cancer -- Chapter 30: Glioma -- Chapter 31: Sarcoma -- Section 5: Inhibitors/clinical trails/cancer -- Chapter 32: Chemistry/synthesis of heparanse inhibitors PI-88, PG -- Chapter 33: PG series/biology/Tumor models and clinical trial -- Chapter 34:Chemically modified heparins/Heparin mimetics -- Chapter 35: Medicinal Chemistry (Ronesparstat/small molecules/clinical trials) - Section 6: Other indications/diseases -- Chapter 36: IBD/inflammation and cancer/diabetes/obesity -- Chapter 37: Immune Diabetes -- Chapter 38 Inflammation, Sepsis/Amyloidosis -- Chapter 39: Kidney dysfunction -- Chapter 40: Fibrosis -- Chapter 41: Viral infection -- Chapter 42: Cariomyocytes/Endothelial cell-cardiomyocyte crosstakl in diabetic cariomyopathy -- Chapter 43: Eye research -- Chapter 44: atheroscelerosis, nuclear localization -- Chapter 45: Yona Nadir (coagulation/tissue factor) -- Section 7: Heparanse-2 (Hpa2) -- Chapter 46: Hpa2 gene cloning -- Chapter 47: UFS -- urofacial syndrome/peripheral neuropathy -- Chapter 48: Hpa2: tumor suppressor.
520 3 _aProteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase's multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology.
988 _aSpringer_Biomedlife_23062020
650 7 _aEnzimas proteolíticas
_2embne
_9146220
700 1 _aVlodavsky, Israel
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aSanderson, Ralph D
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aIlan, Neta
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_1http://viaf.org/viaf/121352633
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
_1http://viaf.org/viaf/148105729
776 0 8 _iPrinted edition:
_z9783030345204
776 0 8 _iPrinted edition:
_z9783030345228
776 0 8 _iPrinted edition:
_z9783030345235
830 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v1221
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-34521-1
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b07/2020
_dz
_eo
_zSI